Currently, the technology, which is said to accelerate drug-discovery research, is marketed with mass spectrometers made by Thermo rivals Applied Biosystems and MDS Sciex. That deal, penned in November 2004, calls for MS Vision to sell and service Ionalytics' Selectra technology in
In a statement today, Thermo did not mention that collaboration.
Selectra enhances mass-spectrometer performance by providing an additional dimension of ion separation, Ionalytics said in November. Based on FAIMS technology, Selectra transmits a targeted subset of ions into a mass spectrometer, resulting in improved detection limits, increased selectivity, and increased throughput, the company said.